Screener
Crinetics Pharmaceuticals CRNX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Research and development personnel expenses | (30,649) | (25,627) |
| Research and development stock-based compensation | (19,328) | (11,819) |
| Other research and development (1) | (8,301) | (6,736) |
| Total research and development expenses | (100,081) | (76,240) |
| Selling, general and administrative | ||
| Other selling, general and administrative expenses (2) | (20,442) | (14,774) |
| Selling, general and administrative personnel expenses | (20,037) | (12,093) |
| Selling, general and administrative stock-based compensation | (10,352) | (8,659) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's business segments — R&D?
- Crinetics Pharmaceuticals (CRNX) reported business segments — R&D of $100.08M in Q1 2026.
- How has Crinetics Pharmaceuticals's business segments — R&D changed year-over-year?
- Crinetics Pharmaceuticals's business segments — R&D increased by 31.3% year-over-year, from $76.24M to $100.08M.
- What does business segments — R&D mean?
- This metric represents the total aggregate expenditure on research and development activities across the entire business segment. It is a critical indicator of the company's investment in innovation and its commitment to advancing its drug pipeline. For clinical-stage companies, this is often the primary driver of operating cash burn.
Ask your AI about Crinetics Pharmaceuticals's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude